Alivus Life Sciences Limited — PPTs, 15-05-2025: Investor Presentation

1. Financial Highlights:

Alivus Life Sciences reported Q4 revenue of ₹649.6 Cr, up 21.1% YoY, powered by a 22.6% rise each in generic API and CDMO segments. EBITDA margin expanded by 520 bps to 32.1%, aided by improved product mix and successful launches. Full-year sales grew 7.1%, with GPL business up 8.8% and Non-GPL up 6.3%. PAT stood at ₹141.9 Cr, boosting net margin to 21.8%. Robust free cash flow of ₹232.8 Cr helped cash reserves reach ₹548.7 Cr. Return on invested capital remained strong near 27%, supported by calibrated capex.

2. Strategic Initiatives & Growth Drivers:

Capex plans focus on expanding capacity at Solapur (greenfield 1000 MT), Dahej, and Ankleshwar, with phased rollouts targeting FY26-28. Emphasis is on complex APIs, CDMO scale-up, oncology, iron compounds, and high-potency APIs. Efficiency improvements through process optimization and flow chemistry support sustainability goals. R&D spend rose to ₹80.5 Cr (3.4% of revenue), fueling pipeline growth with 561 DMF/CEP filings and 4 new synthetic molecules.

3. Business Developments:

The CDMO segment added its 4th project this year, with a 5th expected by H2 FY26, signaling ongoing collaboration expansion. Progress in iron complexes and high-potency formulations showcases diversification. Market reach extended to 30+ countries, with regulated markets now accounting for 85% of revenue.

4. Market Position & Competitive Advantage:

With 86% revenue from regulated markets, Alivus commands leadership in key geographies like India, Europe, Japan, and ROW. Chronic therapies (CVS, CNS) contribute 64% of sales, solidifying market presence. Scale advantages and technology adoption underpin stable margins, while steady capacity additions and a strong DMF/CEP portfolio reinforce generic API leadership.

5. Investor Insights:

Margin expansion and strong free cash flow highlight positive growth potential. Capacity build-up and product launches position Alivus for sustainable scale. Execution risks on greenfield expansions and new verticals (oncology, iron complexes) warrant monitoring to gauge long-term value. Operational efficiencies and geographical diversification bolster confidence in steady profit trends.